J Rheumatol:幼年特发性关节炎的新分类标准:儿科风湿病国际试验组织国际共识

2018-10-28 xiangting MedSci原创

目前已达成国际共识,以识别使用历史JIA术语的各种同质性慢性病。

这项研究旨在使用全球范围内的临床和常规实验室指标,按照循证方法,修订目前的幼年特发性关节炎(JIA)国际风湿病学会联盟(ILAR)分类标准,以确定同类的临床组并区分那些通常仅见于成人疾病儿童期的儿童慢性关节炎类型。

整个项目包括四步。这项工作代表了新的临时性儿科风湿病国际试验组织JIA分类标准的第1步(Delphi基于网络的共识)和第2步(国际名义群体技术(NGT)共识会议)。未来将对至少1000名新发JIA患者(第3步)进行大量数据收集,然后进行分析和NGT共识(第4步),从而为JIA分类标准的循证验证提供数据。

在第1步中,实施了三轮Delphi交互以修改7个ILAR JIA类别。在第2步中,实施了47个电子投票问题,以获得新的拟议标准。提出了四种疾病:(a)全身性JIA;(b)类风湿因子阳性JIA;(c)附着点炎/脊椎炎相关性JIA;(d)早发性抗核抗体阳性JIA。其他类型归类在"其他"下。这些将在前瞻性数据收集期间使用描述符列表进行分析,以查看其中一些聚类是否可以识别同类疾病。

目前已达成国际共识,以识别使用历史JIA术语的各种同质性慢性病。这些初步标准将通过专门项目进行正式验证。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944230, encodeId=b2771944230c6, content=<a href='/topic/show?id=bc4d41068c2' target=_blank style='color:#2F92EE;'>#国际共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41068, encryptionId=bc4d41068c2, topicName=国际共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Dec 23 08:15:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894708, encodeId=85461894e08bb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Jan 12 23:15:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265832, encodeId=e1b01265832bb, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422970, encodeId=8fae14229e0cb, content=<a href='/topic/show?id=e2c531819ce' target=_blank style='color:#2F92EE;'>#分类标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31819, encryptionId=e2c531819ce, topicName=分类标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d23750245, createdName=yytms, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944230, encodeId=b2771944230c6, content=<a href='/topic/show?id=bc4d41068c2' target=_blank style='color:#2F92EE;'>#国际共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41068, encryptionId=bc4d41068c2, topicName=国际共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Dec 23 08:15:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894708, encodeId=85461894e08bb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Jan 12 23:15:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265832, encodeId=e1b01265832bb, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422970, encodeId=8fae14229e0cb, content=<a href='/topic/show?id=e2c531819ce' target=_blank style='color:#2F92EE;'>#分类标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31819, encryptionId=e2c531819ce, topicName=分类标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d23750245, createdName=yytms, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944230, encodeId=b2771944230c6, content=<a href='/topic/show?id=bc4d41068c2' target=_blank style='color:#2F92EE;'>#国际共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41068, encryptionId=bc4d41068c2, topicName=国际共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Dec 23 08:15:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894708, encodeId=85461894e08bb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Jan 12 23:15:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265832, encodeId=e1b01265832bb, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422970, encodeId=8fae14229e0cb, content=<a href='/topic/show?id=e2c531819ce' target=_blank style='color:#2F92EE;'>#分类标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31819, encryptionId=e2c531819ce, topicName=分类标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d23750245, createdName=yytms, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
    2018-10-30 lmm397
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944230, encodeId=b2771944230c6, content=<a href='/topic/show?id=bc4d41068c2' target=_blank style='color:#2F92EE;'>#国际共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41068, encryptionId=bc4d41068c2, topicName=国际共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun Dec 23 08:15:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894708, encodeId=85461894e08bb, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Jan 12 23:15:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265832, encodeId=e1b01265832bb, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422970, encodeId=8fae14229e0cb, content=<a href='/topic/show?id=e2c531819ce' target=_blank style='color:#2F92EE;'>#分类标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31819, encryptionId=e2c531819ce, topicName=分类标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d23750245, createdName=yytms, createdTime=Tue Oct 30 02:15:00 CST 2018, time=2018-10-30, status=1, ipAttribution=)]

相关资讯

Arthritis Rheumatol:先天淋巴样细胞和T细胞影响幼年特发性关节炎滑膜液中检测到的IL-17A特征

该研究证明JIA-SFMC中IL-17A特征的强度是由多种淋巴样细胞类型决定的,其中包括NCR-ILC3、IL-17A+CD4+、IL-17A+CD8+和IL-17A+γδT细胞。

Ann Rheum Dis:卡那奴单抗对全身型幼年特发性关节炎和活动性全身特征患者的疗效

卡那奴单抗的治疗反应持续存在,并与糖皮质激素的明显减量或停药相关,治疗留滞率相对较低。

CHMP对RoActemra用于活动性幼年特发性关节炎(sJIA)持积极意见

罗氏制药近日宣布,欧洲人用药品委员会(CHMP)对RoActemra®(托珠单抗)皮下(SC)给药治疗1岁及以上患者的全身性幼年特发性关节炎(sJIA)持积极意见。在患有sJIA的患者中,托珠单抗可单独给药或与甲氨蝶呤(MTX)联合给药。

Ann Rheum Dis:DMARD初治的幼年特发性关节炎中实现非活动性疾病的靶标治疗

最近发病的JIA患者中有71%实现非活动性疾病(发病时间中位数9个月),39%为无药非活动性。

Arthritis Rheumatol:幼年特发性关节炎多关节型患儿的血清S100A8/A9和S100A12水平

血清S100水平不能预测维持CID或急性发作,S100A12水平仅与到急性发作的时间呈中度负相关。

Semin Arthritis Rheu:依那西普浓度和免疫原性不会影响幼年特发性关节炎患者对依那西普的反应

这项研究在一个大型的JIA患者人群中未证明JIA活动性与循环ETN水平之间存在任何相关性。